Pharmaceutical

Idorsia reacquires aprocitentan rights from Janssen for $343m

Amid financial issues, Idorsia is hoping the resistant hypertension drug would boost the company’s profits.

Sep 7, 2023 - 20:00
Idorsia reacquires aprocitentan rights from Janssen for $343m
Amid financial issues, Idorsia is hoping the resistant hypertension drug would boost the company’s profits.
Read the original article

Tags:

Previous Article

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter

Next Article

Revvity introduces advanced preclinical imaging tech for scientists to make brea...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The changing of the guard is expected in the Crohn’s disease marketplace

The changing of the guard is expected in the Crohn’s di...

Sep 1, 2023

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

How did hiring in the Asia-Pacific pharma industry perf...

Jul 29, 2023

Moderna reports $1.2bn net loss in Q1 2024

Moderna reports $1.2bn net loss in Q1 2024

May 5, 2024